Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aziz Al-Shafi Ismail

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
International Journal of Diabetes in Developing Countries|February 19, 2010
Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?Sayeeda Rahman, Aziz Al-Shafi Ismail, Abdul Rashid A Rahman
Diabetes, Obesity & Metabolism|October 11, 2007
Diabetes-associated macrovasculopathy: pathophysiology and pathogenesisSayeeda Rahman, Tahminur Rahman, Aziz Al-Shafi Ismail, et al.
Clinical Pharmacology : Advances and Applications|February 1, 2012
Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?Sayeeda Rahman, Aziz Al-Shafi Ismail, Shaiful Bhari Ismail, et al.
European Journal of Clinical Pharmacology|June 15, 2007
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled studySayeeda Rahman, Aziz Al-Shafi Ismail, Shaiful Bhari Ismail, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
International Journal of Diabetes in Developing Countries|February 19, 2010
Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?Sayeeda Rahman, Aziz Al-Shafi Ismail, Abdul Rashid A Rahman
Diabetes, Obesity & Metabolism|October 11, 2007
Diabetes-associated macrovasculopathy: pathophysiology and pathogenesisSayeeda Rahman, Tahminur Rahman, Aziz Al-Shafi Ismail, et al.
Clinical Pharmacology : Advances and Applications|February 1, 2012
Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?Sayeeda Rahman, Aziz Al-Shafi Ismail, Shaiful Bhari Ismail, et al.
European Journal of Clinical Pharmacology|June 15, 2007
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled studySayeeda Rahman, Aziz Al-Shafi Ismail, Shaiful Bhari Ismail, et al.
Pageof 1